Regeneron/$REGN
1D1W1MYTD1Y5YMAX
Capital at risk
About Regeneron
Regeneron Pharmaceuticals discovers, develops, and commercializes products that fight eye disease, cardiovascular disease, cancer, and inflammation. The company has several marketed products, including low-dose Eylea and Eylea HD, approved for wet age-related macular degeneration and other eye diseases; Dupixent in immunology; Praluent for LDL cholesterol lowering; Libtayo in oncology; Kevzara in rheumatoid arthritis; and Lynozyfic for multiple myeloma. Regeneron has multiple partnerships and collaboration agreements, with Sanofi (Dupixent, others) and Bayer (Eylea) as its largest partners.
- Ticker
- $REGN
- Sector
- Health
- Primary listing
- NASDAQ
- Employees
- 15,410
- Headquarters
- Tarrytown, United States
- Website
- www.regeneron.com
Regeneron Metrics
BasicAdvanced
$75B
18.56
$40.43
0.19
$3.70
0.50%
Price and volume
Market cap
$75B
Beta
0.19
52-week high
$859.34
52-week low
$541.00
Average daily volume
711K
Dividend rate
$3.70
Financial strength
Current ratio
4.288
Quick ratio
2.633
Long term debt to equity
0.063
Total debt to equity
0.085
Dividend payout ratio (TTM)
8.74%
Interest coverage (TTM)
75.34%
Profitability
EBITDA (TTM)
4,702.4
Gross margin (TTM)
44.46%
Net profit margin (TTM)
27.86%
Operating margin (TTM)
26.87%
Effective tax rate (TTM)
16.21%
Revenue per employee (TTM)
$1,010,000
Management effectiveness
Return on assets (TTM)
6.53%
Return on equity (TTM)
14.04%
Valuation
Price to earnings (TTM)
18.562
Price to revenue (TTM)
4.993
Price to book
2.37
Price to tangible book (TTM)
2.48
Price to free cash flow (TTM)
21.695
Free cash flow yield (TTM)
4.61%
Free cash flow per share (TTM)
34.593
Dividend yield (TTM)
0.49%
Forward dividend yield
0.50%
Growth
Revenue change (TTM)
9.29%
Earnings per share change (TTM)
1.91%
3-year revenue growth (CAGR)
7.03%
10-year revenue growth (CAGR)
12.82%
3-year earnings per share growth (CAGR)
2.25%
10-year earnings per share growth (CAGR)
20.22%
What the Analysts think about Regeneron
Analyst ratings (Buy, Hold, Sell) for Regeneron stock.
Analyst projections of the future price of Regeneron stock.
Bulls say / Bears say
Dupixent remains a powerful growth engine: global sales rose 38% to $6.0 billion in the second quarter. Regeneron also fully repaid its Sanofi development balance, removing a previous deduction from collaboration profits and allowing it to record a larger share going forward. (Nasdaq, Motley Fool)
EYLEA HD is successfully taking over from the older product, with US sales up 52% to $596 million and physician demand up sequentially. Its expanded dosing options, including intervals of up to 20 weeks in key retinal diseases, could support further adoption. (Nasdaq)
Regeneron has several opportunities to broaden its revenue base beyond EYLEA and Dupixent. Its roughly 50 clinical assets include cemdisiran, which has received FDA priority review for generalised myasthenia gravis, while the FDA has also approved Pasatru for fibrodysplasia ossificans progressiva. (Nasdaq, OTC Markets)
The EYLEA franchise remains under pressure: US EYLEA sales fell 45% year on year in the second quarter, while total EYLEA sales had already declined in the first quarter. Biosimilars, rival treatments and the switch to EYLEA HD could keep eroding the legacy product faster than the newer product replaces it. (Reuters, Nasdaq)
Dupixent is a major growth dependency, but management expects its growth to moderate in the second half as recent indication launches annualise and comparisons become tougher. A slowdown would matter disproportionately because Regeneron receives its economics through the Sanofi collaboration. (Motley Fool, Reuters)
Regeneron is spending heavily to replenish its pipeline: 2026 GAAP research and development guidance is $6.5–$6.635 billion, and second-quarter adjusted EPS included a $1.02 per-share acquired in-process research and development charge. This creates earnings volatility before future programmes are proven and commercialised. (Nasdaq, Last10K)
Data summarised monthly by Lightyear AI. Last updated on 28 Sept 2026.
Regeneron Financial Performance
Revenues and expenses
Regeneron Earnings Performance
Company profitability
Upcoming events
No upcoming events
Regeneron News
AllArticlesVideos
Funds containing Regeneron
AllUSDGBPEUR
Fund name | Fund size | $REGN weighting |
|---|---|---|
iShares Nasdaq US Biotechnology$BTEC | $1.2B | 5.24% |
iShares Nasdaq US Biotechnology£BTEK | £865M | 4.97% |
iShares S&P 500 Health Care Sector€IUHE | €125M | 1.19% |
iShares Ageing Population€AGED | €822M | 0.60% |
iShares MSCI World Health Care Sector Advanced€CBUF | €606M | 0.48% |
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Real-time US market data is sourced from the IEX order book provided by Polygon. After-hours US market data is 15 minutes delayed and may differ significantly from the actual tradable price at market open.